Trials / Not Yet Recruiting
Not Yet RecruitingNCT06708871
Thermal Ablation Versus Parathyroidectomy for Primary Hyperparathyroidism
Thermal Ablation Versus Parathyroidectomy for Primary Hyperparathyroidism: a Multicenter Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 520 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, multicenter study designed to compare the efficacy and safety of surgical treatment versus ablation therapy (including radiofrequency ablation and microwave ablation) for patients with primary hyperparathyroidism (PHPT). The study will assess the impact of both treatment modalities on serum parathyroid hormone (iPTH) and calcium levels, clinical symptom improvement, bone mineral density enhancement, reduction in the incidence of urinary system stones, and postoperative complication rates. While surgical treatment has been the standard of care for PHPT, offering definitive cure, it carries inherent surgical risks and complications. Ablation therapy, as a minimally invasive approach, presents a novel alternative with reduced trauma and fewer complications. The outcomes of this study will inform clinical decision-making and potentially optimize treatment strategies for patients with PHPT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Thermal ablation | Thermal ablation is a minimally invasive procedure used to treat primary hyperparathyroidism, a condition where one or more of the parathyroid glands produce excessive amounts of parathyroid hormone (PTH). The treatment involves using heat to destroy the overactive parathyroid tissue. This can be done through various methods such as radiofrequency ablation (RFA) and microwave ablation(MWA). |
| PROCEDURE | Parathyroidectomy | Parathyroidectomy is a surgical procedure to remove one or more of the parathyroid glands in cases of hyperparathyroidism. |
Timeline
- Start date
- 2024-11-26
- Primary completion
- 2028-11-26
- Completion
- 2028-12-26
- First posted
- 2024-11-27
- Last updated
- 2024-11-27
Source: ClinicalTrials.gov record NCT06708871. Inclusion in this directory is not an endorsement.